Randomized double‐blind placebo‐controlled cosmetic trial of a topical first‐in‐class Neutraligand targeting the chemokine TARC/CCL17 in mild‐to‐moderate atopic dermatitis
- Published on 02/12/2024
- Reading time: 4 min.
Nelly Frossard 1, Alexandra Coïc 2, Thibaut Saguet 3, Alain Coïc 2, Franck Himbert 2, Quoc Tuan Do 2, Jean‐Luc Galzi 4, Carey Suehs 5, Gerald Guillaumet 6, Pascal Bonnet 6, Philippe Bernard 2
1
Faculty of Pharmacy
UMR7200, LIT, CNRS‐Strasbourg University
Illkirch
France
2
GreenPharma SAS
Orléans
France
3
TS Consulting
Olivet
France
4
UMR7242, CNRS‐Strasbourg University, ESBS
Illkirch
France
5
Department of Respiratory Diseases
University Hospitals
Montpellier
France
6
Institute of Organic and analytical chemistry
Orleans University
Orléans
France
Abstract
Background Atopic dermatitis has a marked economic impact and affects the quality of life. A cosmetic compound with an innovative strategy is proposed here as a small chemical neutraligand, GPN279 (previously identified as a theophylline derivative), that binds and potently neutralizes the TARC/CCL17 chemokine, activating the Th2 cell‐expressed CCR4 receptor.
Objective Our objective was to evaluate the safety and activity of topically applied GPN279...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Dermatology
Receive our newsletter to stay up to date with the latest news in Dermatology
